Press release
Neurodegenerative Diseases Drugs Market Size to Hit US$ 85.0 Bn by 2032: Persistence Market Research
Neurodegenerative Diseases Drugs Market
According to Persistence Market Research, the most significant share of the market is captured by immunomodulators, thanks to their effectiveness in targeting neuroinflammatory pathways. North America remains the dominant region in 2025, holding an estimated 51.8% share, driven by policy support, reimbursement expansions, and advanced diagnostic infrastructure. Meanwhile, multiple sclerosis is the leading segment by disease indication, supported by high funding levels, accessible biomarkers, and effective drug pipelines.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35538
Key Highlights from the Report
• The market is projected to grow from US$ 58.4 Bn in 2025 to US$ 85.0 Bn by 2032.
• Immunomodulators are expected to account for nearly 43.5% market share in 2025.
• Multiple sclerosis remains the top disease segment due to a strong development pipeline.
• Shift from symptomatic treatment to biologics and immunotherapy is driving innovation.
• North America leads due to robust diagnostics, FDA approvals, and expanded reimbursements.
• Regulatory momentum and investment in biomarkers are reshaping early diagnosis.
Market Segmentation
Drug Class and Therapeutic Category
The drug class segmentation includes immunomodulators, interferons, decarboxylase inhibitors, dopamine agonists, and others. Immunomodulators are forecast to dominate with 43.5% of the market share in 2025, especially in diseases like multiple sclerosis that have a clear autoimmune basis. These drugs are also supported by regulatory momentum and strong clinical endpoints. Interferons, although earlier-generation treatments, remain vital in certain MS regimens due to their anti-inflammatory benefits.
Dopamine agonists are rapidly gaining ground in Parkinson's treatment strategies, increasingly being used to delay levodopa initiation and reduce long-term motor complications. These include drugs like pramipexole, ropinirole, and rotigotine, which are showing efficacy in early-stage disease management, especially when combined with advanced delivery systems.
Disease Indication and End-Use Segments
By disease indication, the neurodegenerative diseases drugs market is segmented into multiple sclerosis, Alzheimer's disease, Parkinson's disease, spinal muscular atrophy (SMA), and others. Among these, multiple sclerosis is projected to lead with over 62.6% share in 2025, largely due to its well-defined biomarkers and growing number of approved disease-modifying therapies.
Alzheimer's disease follows closely due to its high patient burden and growing global prevalence. It is the most researched indication due to rising political support, massive investment in drug trials, and the societal cost of caregiving. Furthermore, end-users such as hospitals, neurology clinics, and specialty centers are increasingly adopting combination therapy protocols to improve patient outcomes.
Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/neurodegenerative-disease-drugs-market.asp
Regional Insights
North America
North America, primarily driven by the United States, is poised to dominate the market, fueled by aggressive funding, early diagnosis efforts, and high regulatory approval rates. With the FDA's full approval of Leqembi (lecanemab) for early-stage Alzheimer's, and the CMS expanding coverage, both investors and care providers are accelerating drug rollout. Canada, while supportive, is more cost-conscious, limiting certain reimbursements.
Europe
In Europe, stringent health economics assessments influence market entry. Regulatory bodies such as the EMA and the German G-BA are cautious, often requiring long-term cost-effectiveness data. However, public-private partnerships under the Innovative Health Initiative (IHI) are funding cutting-edge neurodegenerative research. Countries like Germany, France, and the UK are investing in real-world data to evaluate therapeutic outcomes.
Market Drivers
The push toward early diagnosis is a primary growth catalyst. As new drugs like lecanemab and donanemab target preclinical or early-stage Alzheimer's, healthcare systems are ramping up diagnostics like PET scans, CSF biomarker assays, and blood-based tests. These innovations are expanding the treatable patient base and reinforcing demand for biomarker-guided therapies. As a result, pharmaceutical pipelines are realigning to develop treatments for prodromal and mild cognitive impairment stages.
Market Restraints
Despite approvals, diagnostic gaps and reimbursement biases are slowing real-world adoption of new therapies. Clinicians remain wary of drugs that require expensive diagnostic confirmation, such as amyloid PET scans or lumbar punctures for CSF analysis. Additionally, traditional reimbursement structures continue to favor low-cost symptomatic treatments like levodopa and donepezil, creating resistance to newer, higher-cost drugs without long-term data.
Market Opportunities
Stem cell therapies and gene-based approaches are opening new frontiers in the market. The launch of iPSC-based dopamine cell therapy trials for Parkinson's by BlueRock Therapeutics signals growing confidence in regenerative medicine. Drug developers are now exploring combination treatments where stem cells are supported by immunomodulators or anti-inflammatory agents to enhance engraftment and efficacy. This shift represents a move from maintenance therapies to potential cures.
Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35538
Reasons to Buy the Report
• Offers detailed market forecasts and segmentation through 2032.
• Includes strategic analysis of key players and late-stage clinical candidates.
• Provides insights into regulatory frameworks across major regions.
• Covers disruptive technologies like stem cell therapy and antisense drugs.
• Utilizes expert-verified statistics from Persistence Market Research.
Frequently Asked Questions (FAQs)
• How big is the neurodegenerative diseases drugs market expected to be by 2032?
• Who are the key players in the global market for neurodegenerative diseases drugs?
• What is the projected growth rate of the neurodegenerative diseases drugs market?
• What is the market forecast for neurodegenerative diseases drugs for 2032?
• Which region is estimated to dominate the industry through the forecast period?
Company Insights
Leading Companies Operating in the Market
• Biogen
• Pfizer, Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Orion Pharma
• UCB S.A
• ACADIA Pharmaceuticals Inc.
• Lundbeck A/S
• Mitsubishi Tanabe Pharma Corporation
• Others
Recent Market Developments
• In July 2025, Klotho Neurosciences received FDA Orphan Drug Designation for its gene therapy KLTO-202 targeting ALS.
• In March 2025, Alpha Cognition Inc. launched ZUNVEYL, a new treatment for mild-to-moderate Alzheimer's disease, targeting accessible and cost-effective care solutions.
Conclusion
The neurodegenerative diseases drugs market is at a crucial juncture where innovations in biologics, diagnostics, and regenerative medicine are pushing boundaries. The market is evolving from a symptomatic treatment landscape to one focused on disease modification, early intervention, and personalized medicine. As pharmaceutical companies expand their pipelines, and public health bodies recognize the burden of conditions like Alzheimer's and Parkinson's, the demand for effective therapies is only set to rise.
Persistence Market Research's insights validate that biomarker-enabled diagnosis, immunomodulation, and patient stratification are the future pillars of this high-growth sector. Although reimbursement and diagnostic challenges persist, the industry is witnessing a paradigm shift toward precision neurology. With evolving drug classes, expanding indications, and global collaborations, stakeholders across the spectrum-from payers and providers to patients-stand to benefit in the years ahead.
Read More Related Reports:
Facial Aesthetics Market https://www.persistencemarketresearch.com/market-research/facial-aesthetics-market.asp
Medical And Industrial Gloves Market https://www.persistencemarketresearch.com/market-research/medical-and-industrial-gloves-market.asp
Home Care Services Market https://www.persistencemarketresearch.com/market-research/home-care-services-market.asp
Bone And Joint Health Supplements Market https://www.persistencemarketresearch.com/market-research/bone-and-joint-health-supplements-market.asp
Scoliosis Management Market https://www.persistencemarketresearch.com/market-research/scoliosis-management-market.asp
Lithotripsy Devices Market https://www.persistencemarketresearch.com/market-research/lithotripsy-devices-market.asp
Contact Us:
Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com
About Persistence Market Research:
At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.
Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurodegenerative Diseases Drugs Market Size to Hit US$ 85.0 Bn by 2032: Persistence Market Research here
News-ID: 4161422 • Views: …
More Releases from Persistence Market Research
Insulin Pens Market Revenue Hits US$ 8,406.90 Million in 2025, According to Pers …
The insulin pens market has seen remarkable transformation over the past decade, driven by a combination of technological advancement, increasing diabetes prevalence, and the growing shift toward patient-centric care. According to Persistence Market Research, the global insulin pens market generated revenue of US$ 8,406.90 million in 2025 and is projected to grow at a CAGR of 8.2%, reaching US$ 14,595.80 million by 2032.
Compared to traditional insulin delivery methods like vials…
Microneedle Patches Market to Grow at 7.1% CAGR Through 2032, Says Persistence M …
Microneedle patches have emerged as a transformative solution in the realm of drug delivery systems. As medical science increasingly shifts toward patient-centric, pain-free, and user-friendly solutions, microneedle patches are gaining significant attention for their potential to revolutionize how vaccines, medications, and cosmetic treatments are administered. These tiny, minimally invasive devices offer a bridge between transdermal patches and injectable therapies, combining convenience, safety, and efficacy.
The global microneedle patches market has shown…
Bone Growth Stimulator Market Demand and Opportunities Highlighted by Persistenc …
The global bone growth stimulator market is witnessing robust expansion, propelled by increasing orthopedic conditions, rising geriatric populations, and growing demand for non-invasive treatments. These devices, used to accelerate bone healing in cases of fractures, delayed unions, or non-unions, are becoming essential tools in modern orthopedic treatment. As per recent research by Persistence Market Research, the market is poised to grow from US$2.26 Bn in 2024 to US$3.31 Bn by…
Sexually Transmitted Disease Testing Market Trends and Forecast by Persistence M …
The sexually transmitted disease (STD) testing market is witnessing a notable upsurge driven by rising global infection rates and technological advancements in diagnostics. According to Persistence Market Research, the market is poised to grow from US$10.03 Bn in 2024 to an estimated US$17.08 Bn by 2031, at a robust CAGR of 7.9%. The increasing incidence of STDs such as HIV, gonorrhea, chlamydia, and syphilis is compelling both public and private…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
